Review Article
A System Review and Meta-Analysis of Canaloplasty Outcomes in Glaucoma Treatment in Comparison with Trabeculectomy
Table 1
Characteristics and baseline information of included literatures.
| | Study type | Age, mean (SD) | Male% | Eyes at baseline | POAG% | Baseline IOP, mean (SD) | Baseline AGMs, mean (SD) |
| Canaloplasty standalone | Ayyala et al. [10] | Retrospective | 68.3 (10.0) | 52 | 33 | NA | 21.2 (6.6) | 2.5 (0.8) | Barnebey [11] | Retrospective | 68.2 (13.1) | 55 | 20 | 100 | 23.4 (4.3) | 2.2 (1.2) | Brandao et al. [12] | Prospective | 71.3 (7.3) | 41 | 19 | 74 | 24.6 (5.3) | 2.5 (0.8) | Bruggemann and Muller [13] | Retrospective | 62.7 (NA) | 52 | 21 | 100 | 28.8 (9.6) | 2.9 (1.0) | Brusini [14] | Prospective | 63.5 (14.0) | NA | 214 | 74 | 29.4 (7.9) | 3.3 (0.9) | Gandolfi et al. [15] | Retrospective | NA | 67 | 24 | 67 | 26.0 (4.0) | 2.7 (3.3) | Grieshaber et al. [16] | Prospective | 49.8 (15.7) | 43 | 60 | 100 | 45.0 (12.1) | NA | Grieshaber et al. [17] | Prospective | 70.8 (8.4) | 49 | 47 | 100 | 26.8 (5.2) | 2.8 (0.5) | Grieshaber et al. [18] | Prospective | 71.8 (8.8) | 41 | 22 | 100 | 27.1 (5.3) | 2.9 (0.6) | Kalin-Hajdu et al. [19] | Retrospective | 40.0 (19.2) | NA | 19 | 0 | 30.4 (8.4) | 3.7 (0.8) | Lewis et al. [20] (CP) | Prospective | 67.6 (11.6) | 47 | 103 | 89 | 23.5 (4.5) | 1.9 (0.8) | Lommatzsch et al. [7] | Retrospective | 40.7 (21.8) | 25 | 14 | 0 | 27.1 (12.3) | 2.7 (1.1) | Lopes-Cardoso et al. [21] (CP) | Prospective | 73.4 (6.0) | 66 | 11 | 37 | 24.5 (5.1) | 3.4 (0.5) | Matlach et al. [22] | RCT | 66.5 (11.3) | 60 | 30 | 43 | 23.7 (5.1) | 2.6 (1.6) | Matthaei et al. [23] (CP) | Retrospective | 65.2 (12.4) | 46 | 33 | 87 | 18.5 (6.3) | 2.3 (1.2) | Moelle et al. [24] | Retrospective | 62 (9) | 42 | 26 | 54 | 21.1 (5.8) | 2.5 (1.8) | Seuthe et al. [25] | Retrospective | 66.7 (11.4) | NA | 417 | 86 | 20.9 (3.5) | 3.5 (0.9) | Thederan et al. [26] | Retrospective | 72.9 (5.2) | 64 | 22 | 68 | 23.7 (7.6) | 3.1 (1.2) | Voykov et al. [27] | Retrospective | 60 (11) | 45 | 20 | 75 | 25.7 (6.6) | 3.4 (0.5) | Wang et al. [28] | Retrospective | 39.1 (13.8) | 77 | 17 | NA | 24.7 (8.7) | 2.4 (1.7) | Xin et al. [29] | Prospective | 38 (12.8) | 65 | 17 | 100 | 29.9 (8.2) | 2.9 (0.9) | Canaloplasty with phacoemulsification | | Arthur et al. [30] | Retrospective | 76.1 (8.3) | 56 | 32 | 84 | 18.2 (5.1) | 1.3 (0.7) | Lewis et al. [20] (PCP) | Prospective | 67.6 (11.6) | 47 | 30 | 89 | 23.5 (5.2) | 1.5 (1.0) | Lopes-Cardoso et al. [21] (PCP) | Prospective | 73.4 (6.0) | 66 | 24 | 37 | 19.8 (6.8) | 3.3 (0.5) | Matlach et al. [31] | Retrospective | 72.9 (5.7) | 47 | 19 | 47 | 28.3 (4.1) | 2.8 (1.1) | Matthaei et al. [23] (PCP) | Retrospective | 65.2 (12.4) | 46 | 13 | 87 | 17.5 (4.2) | 2.5 (1.3) | Rekas et al. [32] | RCT | 74.6 (8.9) | 59 | 29 | 83 | 19.0 (6.9) | 2.6 (0.7) | Schoenberg et al. [33] | Retrospective | 66.8 (8.5) | 67 | 36 | 94 | 19.5 (5.7) | NA | Canaloplasty with or without phacoemulsification, mixed results | | Alobeidan and Almobarak [34] | Retrospective | 53.4 (15.0) | 60 | 105 | 67 | 19.0 (6.7) | 2.6 (1.3) | Fujita et al. [35] | Retrospective | 71.7 (8.5) | NA | 11 | 100 | 23.4 (5.5) | 2.8 (0.6) | Rekas et al. [36] | Prospective | 69.3 (11.4) | 40 | 10 | 90 | 19.1 (3.4) | 2.2 (1.1) |
|
|
AGM: antiglaucoma medication; CP: independent canaloplasty subgroup in corresponding literature; NA: data not available; PCP: phacocanaloplasty subgroup in corresponding literature; POAG: primary open-angle glaucoma; RCT: randomized controlled trials.
|